Free shipping on all orders over $ 500

Sorafenib (BAY 43-9006)

Cat. No. M3026
Sorafenib (BAY 43-9006) Structure

BAY 43-9006

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mM*1mL in DMSO USD 40  USD40 In stock
10mg USD 28  USD28 In stock
50mg USD 40  USD40 In stock
100mg USD 50  USD50 In stock
500mg USD 70  USD70 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Sorafenib (BAY 43-9006) is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is also a ferroptosis activator.

Product Citations
Customer Product Validations & Biological Datas
Source Phytomedicine (2015). Figure 1. Sorafenib was purchased from AbMole (Shanghai, China)
Method Cell viability was determined by MTT assay
Cell Lines HCC HepG2
Concentrations 0~100 µM
Incubation Time 24, 48, 72 hours
Results PPI dose- and time-dependently inhibited the proliferation of HepG2 cells, with IC50 values of 1.047 ± 0.376µM within 24 h. Sorafenib was used as a positive control in HepG2 cells.
Protocol (for reference only)
Cell Experiment
Cell lines PLC/PRF/5, Hep3B, HepG2, HuH7
Preparation method PLC/PRF/5, Hep3B, HepG2 and HuH7 Cells were seeded in 96-well plates (3,000 cells/well) and incubated overnight for attachment, and were then treated with indicated agents in 10% FBS supplemented medium for 72 hours. The medium was replaced with MTT (0.5 mg/ml) at 37°C for 2 hours. After removal of medium, the cells were lysed with 200 μl per well dimethyl sulfoxide (DMSO), and absorbance at 570 nm was measured and the values of 50% inhibition concentration (IC50) for each drug were determined.
Concentrations 0, 0.25, 0.5,1, 2 µM
Incubation time 72 hours
Animal Experiment
Animal models PLC/PRF/5 xenograft model in female athymic nude mice of 4–5 weeks of age
Formulation Dissolved in Cremophor EL/ethanol (50:50; Sigma Cremophor EL, 95% ethanol) at 4 × concentration.
Dosages 60 mg/kg
Administration Po, qd
Chemical Information
Molecular Weight 464.82
Formula C21H16ClF3N4O3
CAS Number 284461-73-0
Solubility (25°C) DMSO 45 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Qiujie Wang, et al. Cell Death Dis. GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis

[2] Jialei Sun, et al. Redox Biol. Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation

[3] Xin Chen, et al. Nat Rev Clin Oncol. Broadening horizons: the role of ferroptosis in cancer

[4] Scott M Wilhelm, et al. Cancer Res . BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

[5] Xiufeng Jiang, et,al. Oncotarget, Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma

Related Raf Products

Tinlorafenib (PF-07284890) is an orally active BRAF kinase inhibitor, with IC50 values of 4.25 and 2.7 nM for BRAFV600E/V600K respectively.


Vemurafenib (PLX4032; RG7204; RO5185426) is a first-in-class selective B-RAF inhibitor that inhibits the activity of RAFV600E and c-RAF-1 with IC50 at 31 nM and 48 nM, respectively.


Vemurafenib (PLX4032; RG7204; RO5185426) is a first-in-class selective B-RAF inhibitor that inhibits the activity of RAFV600E and c-RAF-1 with IC50 at 31 nM and 48 nM, respectively. Vemurafenib can induce autophagy.


LUT014, a B-Raf inhibitor with an IC50 value of 11.7 nM, was developed for the study of reducing acne-like lesions associated with EGFR inhibitors at restricted doses.


GNE-9815 is one of the most selective kinase inhibitors of RAF, targeting KRAS mutant cancers by combination of drugs.

Abmole Inhibitor Catalog

Keywords: Sorafenib (BAY 43-9006), BAY 43-9006 supplier, Raf, inhibitors, activators

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.